Liminatus Pharma Inc Dossier - Source-backed chat

Liminatus Pharma Inc

LIMNNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.81

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $3.75Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $5M

Enterprise Value $4.6M

Shares Outstanding 1.3M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Liminatus Pharma, Inc. (NASDAQ: LIMN) is a clinical-stage biopharmaceutical company facing severe liquidity constraints, a massive capital deficit, and imminent Nasdaq delisting risk. While the proposed all-stock acquisition of InnocsAI LLC adds a compelling portfolio of clinical and preclinical CAR-T assets (including IBC101 and INC101), the transaction requires the issuance of 1.6 billion common shares at $0.20 per share, threatening massive dilution to existing shareholders. Furthermore, the company's lead candidate, IBA101 (a second-generation CD47 blocker), is not scheduled to enter Phase 1 clinical trials until early 2027, leaving a long development timeline with no near-term commercial revenues. Given these fundamental headwinds, a Sell recommendation is warranted.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.0525%

The Nasdaq Hearings Panel denies the appeal, leading to immediate delisting and a collapse in trading liquidity. The InnocsAI merger fails to close due to a lack of stockholder approval or inability to meet closing conditions. Severe cash depletion forces the company to halt preclinical operations or undergo a highly dilutive restructuring, wiping out remaining equity value.

Base CaseCentral scenario

$0.1860%

Liminatus struggles to maintain its Nasdaq listing and may be forced to transition to the OTC market, which would severely limit its access to institutional capital. The InnocsAI merger is approved but results in massive dilution, keeping the share price depressed. Clinical development of IBA101 and the newly acquired CAR-T assets progresses slowly due to tight cash resources, with the company relying on highly dilutive micro-cap equity offerings to survive.

Bull CaseUpside scenario

$0.3915%

The proposed merger with InnocsAI is successfully completed, transforming Liminatus into a multi-asset oncology cell therapy player. The Nasdaq Hearings Panel grants a listing extension, and the company successfully secures non-dilutive or strategic partnership funding, mitigating dilution. IBA101 enters the clinic on schedule in early 2027 and demonstrates a superior safety profile by avoiding the severe anemia and thrombocytopenia that plagued first-generation CD47 blockades.

Scenarios reflect our research view at the research date.

Key Investment Merits

Differentiated preclinical safety profile for IBA101, showing no hemolysis or cytopenias in primate toxicology studies up to 100 mg/kg/week.
Strategic expansion into advanced CAR-T therapies via the proposed InnocsAI merger, adding clinical-stage asset IBC101 (CD19xCD22 bivalent CAR-T).
Established clinical collaborations with leading institutions, such as Samsung Medical Center and Seoul St. Mary's Hospital.

Key Investment Risks

Severe liquidity constraints, characterized by a negative shareholder equity of -$9.8 million in FY2025 and a low current ratio.
Imminent Nasdaq delisting risk following non-compliance with the $50M market value of listed securities and $15M market value of publicly held shares requirements.
Massive dilution risk from the proposed issuance of 1.6 billion common shares to acquire InnocsAI.
Long development timelines with lead candidate IBA101 not scheduled to enter Phase 1 trials until early 2027.

Thesis Invalidation Triggers

Securing a major, non-dilutive global licensing or co-development partnership for IBA101 or the InnocsAI CAR-T assets.
Successful execution of a reverse stock split and capital raise that fully restores Nasdaq compliance and provides a multi-year cash runway.
Accelerated clinical timelines or exceptional early efficacy data from the Phase 1/2a trial of IBC101 in South Korea.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.